Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.phrs.2020.104866 http://scihub22266oqcxt.onion/10.1016/j.phrs.2020.104866 32387301!7202852!32387301     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32387301.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Pharmacol+Res 2020 ; 157 (ä): 104866 Nephropedia Template TP {{tp|p=32387301|t=2020. The CoV-2 outbreak: how hematologists could help to fight Covid-19 |pdf=|usr=}}{{32387301}} gab.com Text The CoV-2 outbreak: how hematologists could help to fight Covid-19 JO: Pharmacol Res http://www.kidney.de/pget.php?&tw=1&pmid=32387301 #FOAvip COVID-19 is a medical emergency, with 20 % of patients presenting with severe clinical manifestations. From the pathogenetic point of view, COVID-19 mimics two other well-known diseases characterized by cytokine storm and hyper-activation of the immune response, with consequent organ damage: acute graft-versus-host disease (aGVHD) and macrophage activation syndrome (MAS). Hematologists are confident with these situations requiring a prompt therapeutic approach for switching off the uncontrolled cytokine release; here, we discuss pros and cons of drugs that are already employed in hematology in the light of their possible application in COVID-19. The most promising drugs might be: Ruxolitinib, a JAK1/2 inhibitor, with a rapid and powerful anti-cytokine effect, tyrosine kinase inhibitors (TKIs), with their good anti-inflammatory properties, and perhaps the anti-Cd26 antibody Begelomab. We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed. Twit Text FOAVip The CoV-2 outbreak: how hematologists could help to fight Covid-19 ????Pharmacol Res http://www.kidney.de/pget.php?&tw=1&pmid=32387301 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32387301 #FOAvip English Wikipedia <ref>{{Cite pmid|32387301}}</ref> The CoV-2 outbreak: how hematologists could help to fight Covid-19 #MMPMID32387301 Galimberti S; Baldini C; Barate C; Ricci F; Balducci S; Grassi S; Ferro F; Buda G; Benedetti E; Fazzi R; Baglietto L; Lucenteforte E; Di Paolo A; Petrini M Pharmacol Res 2020[Jul]; 157 (ä): 104866 PMID32387301show ga COVID-19 is a medical emergency, with 20 % of patients presenting with severe clinical manifestations. From the pathogenetic point of view, COVID-19 mimics two other well-known diseases characterized by cytokine storm and hyper-activation of the immune response, with consequent organ damage: acute graft-versus-host disease (aGVHD) and macrophage activation syndrome (MAS). Hematologists are confident with these situations requiring a prompt therapeutic approach for switching off the uncontrolled cytokine release; here, we discuss pros and cons of drugs that are already employed in hematology in the light of their possible application in COVID-19. The most promising drugs might be: Ruxolitinib, a JAK1/2 inhibitor, with a rapid and powerful anti-cytokine effect, tyrosine kinase inhibitors (TKIs), with their good anti-inflammatory properties, and perhaps the anti-Cd26 antibody Begelomab. We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed. |Betacoronavirus/drug effects[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy[MESH] |Graft vs Host Disease/drug therapy[MESH] |Hematology/*methods[MESH] |Humans[MESH] |Macrophage Activation Syndrome/drug therapy[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH]The CoV-2 outbreak: how hematologists could help to fight Covid-19 (epmc).pdf DeepDyve Pubget Overpricing